Division News

  • Kirkpatrick Named 2021-22 University Scholar
    The University of Vermont Graduate College has announced that Beth Kirkpatrick, M.D., professor and chair of microbiology and molecular genetics, has been named one or three 2021-2022 University Scholars. The University Scholars program recognizes distinguished UVM faculty members for sustained excellence in research, scholarship, and creative arts.
  • TGIR Research Slam Highlights Progress One Year into Pandemic
    On March 18, 2021, researchers from across UVM came together via Zoom for the second edition of the Translational Global Infectious Diseases Research Center's COVID-19 research slam, titled “UVM Tackles COVID-19: Research Progress and Perspectives One Year into the Pandemic.”
  • A Matter of Trust: Bringing Vaccine Education to New American Communities
    One of the most alarming realizations of the past year has been the clear link between structural racism in the U.S. and the racial and ethnic health disparities that have led to a disproportionate impact of COVID-19 on communities of color. Thanks to the collaboration of numerous partners in Vermont, members of the New American community are getting the education they need to make informed decisions about their health and the COVID-19 vaccine.
  • Study Warns Mask Mandate Without Education May Raise COVID-19 Spread
    A new study conducted by a team of health economists and public health faculty at the University of Vermont suggests that the behavior public officials are now mandating or recommending to slow the spread of COVID-19--wearing a face covering--should come with a caveat. If not accompanied by proper public education, the practice could lead to more infections.
  • UVM Medical Center & Vaccine Testing Center Complete COVID-19 Vaccine Trial Enrollment
    The UVM Medical Center and Vaccine Testing Center have successfully reached and surpassed the targeted number of enrollees for an ongoing Phase 3 clinical trial of the AstraZeneca COVID-19 vaccine.
  • Developing a COVID-19 Vaccine: Q&A with Beth Kirkpatrick, M.D.
    An internationally recognized physician-scientist, Beth Kirkpatrick, M.D., has a decades-long history of leadership in the field of vaccine testing and development. In 2001, she launched the UVM Vaccine Testing Center (VTC), and since then, the VTC has grown to assume a prominent role in the development and evaluation of vaccines for globally important infectious diseases. The VTC has garnered support from the National Institutes of Health, the Bill & Melinda Gates Foundation, and the U.S. Department of Defense, among others. Kirkpatrick is also principal investigator and director of UVM’s Translational Global Infectious Disease Research Center of Biomedical Research Excellence and Chair of the Department of Microbiology and Molecular Genetics.
  • UVM and UVM Health Network Participate in Phase 3 COVID-19 Vaccine Trial
    The University of Vermont Medical Center and Vaccine Testing Center at the University of Vermont’s Larner College of Medicine have been selected to take part in a Phase 3 trial for a COVID-19 vaccine developed by Oxford University and manufactured by AstraZeneca.
  • Diehl & Colleagues Uncover Critical Information about COVID-19 Immune Response
    New research, published in Clinical and Translational Immunology by UVM Associate Professor Sean Diehl, Ph.D., and colleagues provides a clearer picture of the protective antibodies induced by the SARS-C0V-2 virus and their role in serious illness and what’s needed for full protection.
  • Majumdar Research Shows How SARS-CoV-2 Robs Cell’s Ability to Sound Alarm and Fight
    New research, published by scientists at the University of Vermont and Caltech in the journal Cell, has pinpointed three specific mechanisms that allow SARS-CoV-2 to incapacitate human cells by disabling the cell’s alarm system to call for help or warn nearby cells of infection.
  • Botten, Bruce & Colleagues' Study Describes Streamlined COVID-19 Test
    A team of scientists at the University of Vermont, working in partnership with a group at the University of Washington, has developed a method of testing for the COVID-19 virus that doesn’t make use of these chemicals but still delivers an accurate result, paving the way for inexpensive, widely available testing in both developing countries and industrialized nations like the United States, where reagent supplies are again in short supply.
  • Larner Grants Lead in Record-Setting Year for UVM Research Funding
    The University of Vermont received $181.7 million in research funding during the 2020 fiscal year - the largest in UVM history by a wide margin. The Larner College of Medicine had the largest number of grants.
  • Kirkpatrick Featured in Elemental Article on COVID-19 Vaccine
    (JULY 29, 2020) Comments from Chair and Professor of Microbiology and Molecular Genetics Beth Kirkpatrick, M.D., were featured in a July 29 article, titled "One Man's Quest to Infect People With Covid-19 for Science," in Elemental, a new Medium publication for science-backed health and wellness coverage.
  • Lee and Raszka's Commentary on Kids & COVID-19 Transmission Garners Broad Media Coverage
    (JULY 10-20, 2020) Significant national and international media coverage was generated in response to the publication of a Pediatrics Commentary, titled “COVID-19 Transmission and Children: The Child Is Not to Blame,” authored by Assistant Professor of Pediatrics Benjamin Lee, M.D., and Professor of Pediatrics and Director of Pediatric Infectious Diseases William Raszka, M.D.
  • Kids Rarely Transmit COVID-19, Say Pediatric Infectious Disease Experts Lee and Raszka
    A commentary published in the journal Pediatrics by Benjamin Lee, M.D. and William V. Raszka, Jr., M.D., concludes that children infrequently transmit COVID-19 to each other or to adults and that many schools, provided they follow appropriate social distancing guidelines and take into account rates of transmission in their community, can and should reopen in the fall.
  • Kirkpatrick Quoted in Two ABC News Stories on COVID-19 Vaccine & Antibodies
    (JUNE 19 & 24, 2020) Beth Kirkpatrick, M.D., chair of microbiology and molecular genetics and director of the Vaccine Testing Center, was quoted in two ABCNews.com stories - one on a potential COVID-19 vaccine and the other on the durability of COVID-19 antibodies.
  • TGIR Hosts Virus "Slam" on 2019-nCoV
    University of Vermont scientists, physicians, and students gathered at the Larner College of Medicine February 6 for the first-ever on-campus “virus slam” hosted by the Translational Global Infectious Diseases Research Center. At the event, some twenty experts, from five UVM colleges and institutes, gave five-minute mini-talks that ranged from explaining the biochemistry of the virus’ interaction with the human immune system to interpreting the latest data from the World Health Organization.
  • Research Excellence and Scholarship Highlighted at Annual Celebration Events
    The Larner College of Medicine's fourth annual "Celebrating Excellence in Research" series featured two days of presentations and recognition designed to highlight research performed by junior faculty, senior faculty, postdoctoral trainees, and graduate students at the College.
  • Innovative Research Model Sheds Light on Immune Response in Dengue Infection
    Investigators in UVM's Vaccine Testing Center and Center for Translational Global Infectious Disease Research (TGIR) have uncovered details of the human immune response to infection with dengue - a close "cousin" of the Zika virus - which 40 percent of the global population is at risk for contracting. Their study findings were reported recently in the Lancet’s open-access journal EBioMedicine.
  • $12.3 Million NIH Grant Establishes Translational Global Infectious Disease Research Center
    Leaders at the University of Vermont and Larner College of Medicine announced $12.3 million in funding for a new Center of Biomedical Research Excellence (COBRE) called the “Translational Global Infectious Disease Research Center” (TGIR) that will join together two traditionally distinct groups of scientists to develop innovative approaches to prevent and control infectious disease.
  • Vaccine Testing Center a Site for New NIH Live, Attenuated Zika Vaccine Trial
    Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, Md., and at the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont in Burlington.